showed better response in 0.5mg/kg than PBO groups (OR=8.9, CI1. ps<0.05, respectively). Conclusion: the results did not find significant biomarkers to predict better respons to 0.5mg/kg ketamine but baseline high IL6 and low CRP level may possible do. Moderate reduction of TNF α level with 0.5mg/kg ketamine might be related to initial antiinflammtory effect.
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Effects of CYP2C19 genotype on steady-state plasma concentrations of escitalopram and desmetyl metabolite in Japanese depressed patients of S-enantiomer of citalopram were different between extensive metabolizers and poor metabolizers of CYP2C19 in healthy subjects and depressed patients. Thus, we studied the effects of polymorphisms of CYP2C19 gene on plasma drug concentrations in Japanese depressed patients. Methods: Subjects were 412 depressed patients receiving 5, 10, 15 and 20 mg once a day of escitalopram. The mean ± SD (range) of age and body weight were 43.1 ± 17.3 (19-80) years, and 60.3 ± 13.4 (34-91) kg, respectively. Sample collections were conducted 14-16 h after the bedtime dosing. Plasma concentrations of escitalopram and desmethylescitalopram were quantitated using HPLC. CYP2C19 genotypes were identified using PCR methods. The study was approved by the Ethics Committee of Hirosaki University Hospital, and written informed consent to participate in this study was obtained from the patients. Results: There was no difference in steady-state plasma concentrations of escitalopram in 5, 10, 15 or 20 mg of escitalopram. However, ANOVA showed a significant difference in dose-adjusted plasma concentration of escitalopram but not in dose adjusted plasma concentration of desmethylescitalopram. ANCOVA including age, sex and body weight showed significant differences in dose-adjusted plasma concentration of escitalopram and in ratio of desmethylescitalopram and escitalopram. Conclusion: These findings suggest that the CYP2C19 variants are associated with steady-state plasma concentration of escitalopram but not with desmethylescitalopram.
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The antidepressant-like effect induced by caloric restriction: possible involvement of orexin-A. 
Abstract

Palavras-chave:
Caloric restriction, antidepressant-like effect, BDNF Introduction: Evidence suggests that rats and mice submitted to caloric restriction perform better on learning and memory tests and show behavioral adaptation in animal models of depression. These effects may involve changes in neurotransmitters and neuropeptides important for modulating stress responses, like orexin A (OXA) and brain-derived neurotrophic factor (BDNF). OXA, a neuropeptide produced by neurons in the lateral hypothalamic and perifornical areas. OXA modulates the release of BDNF, a highly expressed neurotrophin, which mediates antidepressant-like effects through interaction with TrkB receptors. Our work tested the hypothesis that CR-induced behavioral effects would involve OXA and BDNF signaling. Methods: BALB/c mice were submiited to CR for 10 days (receiving 60% of the total energy supply based on the control animals) and exposed to forced swimming test (FST). Independent groups were pretreated with K252 (TrkB receptor antagonist; 80ug/kg, ip), SB-334867 (orexin-1 receptor antagonist, 10mg/kg,ip) or vehicle on days 1, 5 and 9 of CR, and were submitted to FST on the 10 th day. Results: CR induced an antidepressant-like effect when compared with ad libitum condition (Two-way ANOVA interaction: F 1,19 =5.287; t test, p<0,005) and this effect was reversed by the pre-treatment with SB-334867 (test t, p>0,005). CR effect was reproduced in the group treated with SB-334867 (two-way ANOVA interaction: F 1,26 =45.01test t, p<0,005), but this effect was not reversed by the pre-treatment with SB-334867 (test t, p>0,005). Conclusion: CR is able to promote antidepressant-like effect, possibly via OXA-OX1R signalling.
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Reversal of stress-induced anhedonia by the multimodel antidepressant, vortioxetine 
